Hormone replacement therapy (HRT): Overview and focus on progestogens
This promotional webinar has been commissioned and funded by Viatris and developed in partnership with Guidelines. Intended for UK healthcare professionals. Products and brand names are mentioned. View Femoston® (estradiol/dydrogesterone) and Femoston® -conti (estradiol/dydrogesterone) prescribing and adverse event reporting information.
FEM-2021-0346 March 2022
Half-day virtual event focusing on practical approaches to management of gastrointestinal disorders and iron deficiency
Information intended for UK healthcare professionals only. This promotional event has been commissioned and funded by Norgine Pharmaceuticals Limited and developed in partnership with Guidelines.
UK-COR-NP-2100043
Date of preparation: July 2021
Hormone replacement therapy (HRT): what is the role of the progestogen?
This promotional video has been commissioned and funded by Viatris and developed in partnership with Guidelines. Intended for UK healthcare professionals. Products and brand names are mentioned. View Femoston® (estradiol/dydrogesterone) and Femoston® -conti (estradiol/dydrogesterone) prescribing and adverse event reporting information.
FEM-2021-0362 March 2022
The impact of DOACs on stroke in patients with NVAF: practical considerations for those with comorbidities
These promotional videos have been funded by Bristol Myers Squibb on behalf of the BMS / Pfizer Alliance and developed in conjunction with Guidelines. The promotional content on this page is intended for UK healthcare professionals only.
View ELIQUIS (apixaban) prescribing and adverse event reporting information
432-GB-2100966 | Date of preparation: January 2022
Targeting the cause of opioid-induced constipation with PAMORAs
This promotional video has been funded by Sandoz Ltd and developed in conjunction with Guidelines. The promotional content on this page is intended for UK healthcare professionals only.
View prescribing information
141580 | Date of preparation: September 2021
Acne vulgaris: management
These videos have been funded by Galderma UK Ltd and developed in conjunction with Guidelines. The content on this page is intended for UK healthcare professionals only.
View Epiduo 0.1%/2.5% (adapalene and benzoyl peroxide) gel prescribing information
View Epiduo 0.3%/2.5% (adapalene and benzoyl peroxide) gel prescribing information
UKI-NBD-2100060 | January 2022
Management of obesity in primary care: a Guidelines algorithm
Information intended for UK healthcare professionals only. These videos have been funded through an arm’s-length sponsorship by Novo Nordisk Limited. Guidelines approached Novo Nordisk Limited to fund the production of these videos.
Date of preparation: December 2021
Diagnosis and initial management of opioid-induced constipation
This promotional video has been funded by Sandoz Ltd and developed in conjunction with Guidelines. The promotional content on this page is intended for UK healthcare professionals only.
View prescribing information
141579 | Date of preparation: September 2021
Opioid-induced constipation: optimal management and the role of PAMORA drugs
These promotional videos have been funded by Sandoz Ltd and developed in conjunction with Guidelines. The promotional content on this page is intended for UK healthcare professionals only.
View prescribing information
141578 | Date of preparation: September 2021
Management of common eye conditions: blepharitis
Fiona Chiu (Moorfields Eye Hospital NHS Foundation Trust) explains the symptoms and management of blepharitis.
Management of common eye conditions: conjunctivitis
Sarah Thomas (Moorfields Eye Hospital NHS Foundation Trust) describes the causes, symptoms, and treatment of conjunctivitis.
Management of common eye conditions: dry eye
Fiona Chiu (Moorfields Eye Hospital NHS Foundation Trust) covers the presentation, causes, and treatment of dry eye.
Sixmo®▼ (buprenorphine) 74.2mg implant SMC2372
The production of this Guidelines card has been commissioned by Accord Healthcare Limited.
View adverse event reporting and prescribing information
UK-03735 April 2022
Tirbanibulin 10mg/g ointment (Klisyri®▼) SMC2395
The production of this Guidelines card has been commissioned by Almirall Ltd.
View prescribing and adverse event reporting information
IE-KLI-2100016 December 2021
Bempedoic acid (Nilemdo®▼) and Bempedoic acid / ezetimibe (Nustendi®▼) SMC card
The production of this Guidelines card has been commissioned and funded by Daiichi Sankyo UK. This content is for healthcare professionals only.
View Bempedoic acid (Nilemdo®▼) & Bempedoic acid and ezetimibe (Nustendi®▼) prescribing and adverse event reporting information
BEM/21/0777 December 2021
NICE Technology Appraisal 651: Naldemedine ▼ for treating opioid‑induced constipation
The production and printing of this Guidelines summary card has been commissioned by Sandoz Ltd. Information intended for UK healthcare professionals only.
View prescribing information
UK/P/RZM/20-0016c October 2020
DuoResp® Spiromax® (budesonide/formoterol)
This promotional prescribing summary card has been developed from content provided by Teva UK Limited. Information intended for UK healthcare professionals only.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Teva UK Limited on 0207 540 7117 or medinfo@tevauk.com.
Click here for prescribing information and adverse event reporting
DUOR-GB-00117
Date of preparation: March 2022
Soolantra® (ivermectin) 10 mg/g cream
This prescribing summary card was developed from content provided by Galderma UK Ltd. Information intended for UK healthcare professionals only.
View Soolantra® (ivermectin) 10 mg/g cream prescribing and adverse event reporting information.
UKI-SOC-2100031 September 2021
Changes to the NICE atrial fibrillation (AF) guideline and anticoagulation treatment options—what do they mean to you?
This promotional animation has been commissioned by Bayer plc and developed in partnership with Guidelines.
View Xarelto▼ (rivaroxaban) prescribing information and adverse event reporting
PP-XAR-GB-2154 December 2021
A national audit of pancreatic enzyme replacement therapy (PERT) prescribing in patients with pancreatic cancer: The RICOCHET study
This supplement has been commissioned and funded by Viatris and developed in partnership with Guidelines.
NON-2021-4065 February 2022
Appropriate use of opioids for chronic pain in primary care
This promotional supplement has been commissioned and funded by Grünenthal and developed in partnership with Guidelines. Information intended for healthcare professionals only.
View PALEXIA® SR tablets (tapentadol hydrochloride) prescribing and adverse event reporting information
M-PLX-UK-10-21-0036 October 2021
Management of hepatic encephalopathy in primary care
This management algorithm has been commissioned and funded by Norgine Pharmaceuticals Limited and developed in partnership with Guidelines. Information intended for UK healthcare professionals only.
View TARGAXAN® (rifaximin-α) prescribing and adverse event reporting information
UK-HEP-XIF-2100040 October 2021
Guideline for the managed introduction of biosimilar bolus insulin in individuals with type 2 diabetes
This guideline was developed by a multidisciplinary expert panel: Down S et al with the support of an educational grant from Sanofi Ltd.
Prescribing combined hormone replacement therapy (HRT) containing dydrogesterone
This promotional algorithm has been commissioned and funded by Viatris and developed in partnership with Guidelines. Intended for UK healthcare professionals.
View Femoston® (estradiol/dydrogesterone) and Femoston® -conti (estradiol/dydrogesterone) prescribing and adverse event reporting information.
FEM-2021-0238 June 2021
Managing obesity in primary care
This management algorithm was developed by a multidisciplinary expert panel: Tahrani et al with the support of an educational grant from Novo Nordisk Limited. Information intended for UK healthcare professionals.
Identifying and managing allergic rhinitis in the asthma population
This management algorithm was developed by a multidisciplinary expert panel: Scadding et al with the support of an educational grant from Mylan.
Osteoporotic fracture guideline
This guideline was developed by a multidisciplinary expert panel: Cooper C et al with the support of an educational grant from UCB Pharma Ltd.
Inhaler choice guideline
This management algorithm was developed by a multidisciplinary expert panel: Usmani et al and supported by Chiesi Ltd through the provision of a grant for its production.
Women of child-bearing age with inflammatory rheumatic diseases guideline
This guideline was developed by a multidisciplinary expert panel: Giles I et al with the support of an educational grant from UCB Pharma Ltd.
Guideline for the managed introduction of biosimilar basal insulin
This guideline was developed by a multidisciplinary expert panel: Down S et al with the support of an educational grant from Mylan.
Medication management of patients with enteral feeding tubes
This guideline was developed by a multidisciplinary expert panel: Wright D et al with the support of a grant from Rosemont Pharmaceuticals Ltd.
Calculating renal function in patients with atrial fibrillation
This animation has been developed and funded by the Bristol Myers Squibb/Pfizer Alliance and is intended for UK healthcare professionals.
432-GB-2100230 June 2021
The role of peripherally acting µ-opioid receptor antagonists (PAMORAs) in the management of opioid-induced constipation (OIC)
This educational reference document has been initiated, commissioned, and developed by Sandoz Ltd. Information intended for UK healthcare professionals only.
View prescribing information
UK/MKT/RZM/20-0029f October 2020
Identify, optimise treatment, refer—treating familial hypercholesterolaemia (FH) in primary care
This eLearning module has been commissioned and funded by Amgen Ltd and developed in partnership with Guidelines.
By logging in to this page you confirm your understanding that you are about to view content intended for UK HCPs only.
The content has been developed in collaboration with, and funded by, Amgen Ltd.
SC-UKIE-AMG145-00785 | December 2021
Managing patients with non-valvular atrial fibrillation (NVAF) and diabetes—a patient case study
This promotional Learning module has been commissioned and funded by Bayer plc and developed in partnership with Guidelines.
View adverse event reporting and prescribing information for Xarelto▼(rivaroxaban)
PP-XAR-GB-2416 March 2022
Transitioning eligible patients with NVAF from warfarin to direct oral anticoagulants—a patient case study
This promotional Learning module has been commissioned and funded by Bayer plc and developed in partnership with Guidelines.
View adverse event reporting and prescribing information for Xarelto▼(rivaroxaban)
PP-XAR-GB-2415 January 2022
Management of venous thromboembolism in primary care
This promotional eLearning module has been funded by Bristol Myers Squibb on behalf of the BMS / Pfizer Alliance and developed in conjunction with Guidelines. The promotional content on this page is intended for UK healthcare professionals only.
View ELIQUIS (apixaban) prescribing and adverse event reporting information
432-GB-2100953 | February 2022